Bill Ackman was right about music. He still barely made money

Pershing Square bought roughly 10% of Universal Music Group in 2021 for about $4 billion. Last week it sold the last of that position for a profit of around $600 million. Five years. One of the best businesses he says he has ever owned. And the return works out to low single digits a year on his largest holding.

That gap, between being right and getting paid, is the whole lesson. Miss it and you will keep copying great investors into mediocre outcomes.

Start with what he got right, because it was almost everything.

Ackman’s thesis on UMG was clean. A royalty on the world’s recorded music. Streaming still compounding. The best management team in the industry. A stock trading at a discount to intrinsic value largely because it was listed in Amsterdam instead of New York, starved of US institutional demand. He called it a blissfully comfortable place to own an asset. On the business, he was not wrong. UMG kept growing. The music did what he said it would.

He was right about the company. He was wrong about his ability to control what happened next.

The thesis needed a catalyst. The catalyst never came.

The whole trade rested on closing the valuation discount, and the plan to close it was a US listing. UMG filed confidentially for a secondary US listing in July 2025. In March 2026 it shelved those plans, citing market conditions. The re-rating Ackman was underwriting quietly walked out the door.

So he tried to force it. In April 2026 Pershing Square put a $64 billion takeover proposal on the table, a plan to merge UMG with his SPARC vehicle and move the primary listing to the New York Stock Exchange. This is the tell. When a passive thesis stops working, the activist reaches for control.

He didn’t have it. Bolloré, UMG’s largest shareholder with nearly 40% of the voting rights, told the offer to get lost. Cyrille Bolloré said the price was not there at all. The board rejected the bid unanimously as a fundamental undervaluation. Days later, Pershing Square placed 80.6 million shares and exited. UMG dropped 7% as the takeover premium evaporated.

Here is the part worth sitting with.

The business thesis held for five years and the trade still underperformed. Not because the analysis was bad. Because the two things that actually drive a return, the timing of the catalyst and his power to force it, were the two things he did not control. A correct view on the asset is not a return. It is a hypothesis waiting on events that may never oblige.

Now apply that to the version of this you actually live: copying a great investor.

When Ackman announced the UMG bid, plenty of people bought the stock on his conviction. Think about what they were actually copying. They took the thesis. They did not take the five-year horizon, the $20 billion fund that can sit through a stalled catalyst without flinching, the board seat, or the balance sheet to launch a $64 billion bid. They inherited the idea and none of the machinery that makes the idea pay.

That is why following blindly rarely works, and the real reason is not that the guru is fallible. It is that you and the guru are playing different games with the same ticker. He can hold a dead-money position for five years across a diversified book and call it patience. You holding the same name for five years is an opportunity-cost wound you feel every quarter. His position sizing, his time horizon, his ability to become the catalyst himself: you copy the stock and inherit none of it.

The name in your portfolio and the name in his are the same three letters. The trade is not the same trade.

So keep the framework, but keep the sharp version.

Even the best investors get outcomes wrong while getting the analysis right. And a thesis is only worth what your horizon, your sizing, and your control let you extract from it. Ackman had all three and still ground out 15% over five years on his best idea. You have the ticker and a screenshot of his tweet.

Copy the thinking if you must. Never copy the position.

If you found this useful, the deeper version of “how to actually read what an investor is doing versus what they’re saying” is the kind of thing I go through live in the Growth Titans sessions. Reply if you want in on the next one.

Register Now 🚀

Growth Titans is back for its 5th edition.

Every earnings season poses the same scheduling problem.

→ Do it early and you miss the season
→ Do it midway and you miss the long tail
→ Do it at the end and it becomes a rear view mirror exercise

So this time we are not choosing. We are doing two.

Session 1 → 16th August 2026, Sunday, 11 AM IST
Session 2 → 13th September 2026, Sunday, 11 AM IST

Session 1 covers the early prints and sets up the thesis. Session 2 catches the long tail, marks the thesis to market, and adds what the first four weeks of results revealed.

Both sessions are bundled under one plan. One payment, both seats.

What is different this edition

→ Lifetime access to recordings
→ Full deck after each session
→ A simple framework to screen inflectors, taught rather than described

What stays the same

→ Global macro setup, then sectors, then names
→ 8 to 10 companies per session, picked on business model or competitive positioning, not on price action
→ An accountability review of what we called last time and what it did

FY28 is shaping up to be a breakout year for a large set of Indian companies. Most of them will not look obvious in the Q1 print. That is the entire point of the exercise.

Register Now 🚀

Disclaimer: Neither Saket Mehrotra nor Beta to Alpha is a SEBI registered investment advisor. Views are my own and do not represent my previous or current employer. Any mention of stocks and securities is not a recommendation to buy/sell. The author may hold positions in the stocks mentioned and sell without prior notice. Please do your own due diligence before investing. The purpose of this newsletter is for educational purposes only.